Adverse effect monitoring should include pharmacovigilance for hypotension secondary to hypovolemia and volume contraction, euglycemic ketoacidosis, acute kidney injury, genital mycotic infections (at risk individuals: elderly, female, uncontrolled hyperglycemia, or prior history), hypoglycemia when combined with insulin, Fournier gangrene, and pyelonephritis [21,22]. The gene discussed is INS; the disease is pyelonephritis.